These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26016726)

  • 1. Characteristics and genotype profiles of antiretroviral-naïve patients entering a Southern US HIV outpatient clinic 2009-2012.
    Seal PS; Frontini M; Jhita PK; Deichmann PC; Clark RA
    Int J STD AIDS; 2016 Jun; 27(7):554-9. PubMed ID: 26016726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
    Yalçınkaya T; Köse S
    Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of antiretroviral drug resistance in antiretroviral-naive individuals.
    James CW; Moffett LE; Szabo S
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):193-5. PubMed ID: 19414829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
    Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rates of baseline antiretroviral resistance among HIV-infected pregnant women in an HIV referral centre in Rio de Janeiro, Brazil.
    de Lourdes Teixeira M; Nafea S; Yeganeh N; Santos E; Gouvea MI; Joao E; Ceci L; Bressan C; Cruz ML; Sidi LC; Nielsen-Saines K
    Int J STD AIDS; 2015 Nov; 26(13):922-8. PubMed ID: 25504831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in HIV drug resistance mutations and virological outcome.
    Mave V; Gahunia M; Frontini M; Clark R; Mushatt D
    J Womens Health (Larchmt); 2011 Jan; 20(1):117-22. PubMed ID: 21190485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.
    Bila DC; Boullosa LT; Vubil AS; Mabunda NJ; Abreu CM; Ismael N; Jani IV; Tanuri A
    PLoS One; 2015; 10(7):e0130580. PubMed ID: 26151752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study.
    Treichel S; Hartmann M; Rump A; Brust J; Schuster D; Mosthaf F; Procaccianti M; Klinker H; Petzoldt D
    Eur J Med Res; 2003 Sep; 8(9):405-13. PubMed ID: 14555296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Antiretroviral Drug Resistance Mutations in HIV Seropositive Patients from an Outpatient Clinic of a Large University Hospital from São Paulo, Brazil.
    Oliveira Constantinov E; Brígido LFM; Fonseca LAM; Casseb J;
    AIDS Res Hum Retroviruses; 2020 Mar; 36(3):200-204. PubMed ID: 31842584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.
    Kebe K; Thiam M; Diagne Gueye NR; Diop H; Dia A; Signate Sy H; Charpentier C; Belec L; Mboup S; Toure Kane C
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):242-9. PubMed ID: 22860571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon.
    Mokhbat JM; Melhem NM; El-Khatib Z; Zalloua P
    J Infect Dev Ctries; 2014 Mar; 8(3):339-48. PubMed ID: 24619266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late presentation and transmitted drug resistance mutations in new HIV-1 diagnoses in Detroit.
    Huaman MA; Aguilar J; Baxa D; Golembieski A; Brar I; Markowitz N
    Int J Infect Dis; 2011 Nov; 15(11):e764-8. PubMed ID: 21840743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
    Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
    J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.